Efficacy and Safety of Once-Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma. -a Phase 2 Multicenter Trial-

被引：0
|
作者：
Kudo, Daisuke [1 ]
Komeno, Takuya [2 ]
Yoshida, Chikashi [2 ]
Tsutsumi, Ikuyo Ota [2 ]
Ohashi, Kazuteru [3 ]
Kakihana, Kazuhiko [3 ]
Kobayashi, Takeshi [3 ]
Doki, Noriko [3 ]
Najima, Yuho [3 ]
Igarashi, Aiko [3 ]
Hori, Mitsuo [4 ]
Okoshi, Yasushi [4 ,5 ]
Fujio, Takayuki [4 ]
Shinagawa, Atsushi [6 ]
Yamamoto, Masahide [7 ]
Takano, Hina [8 ]
Kumagai, Takashi [9 ]
Yamamoto, Koh [10 ]
Toyota, Shigeo [11 ]
Nakamura, Yuichi [12 ]
Kojima, Hiroshi [5 ,13 ]
机构：
[1] Tokyo Kita Med Ctr, Dept Hematol, Tokyo, Japan
[2] Natl Hosp Org Mito Med Ctr, Dept Hematol, Ibaraki, Japan
[3] Komagome Hosp, Hematol Div, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[4] Ibaraki Cent Hosp, Dept Hematol, Ibaraki, Japan
[5] Univ Tsukuba Hosp, Ibaraki Clin Educ & Training Ctr, Ibaraki, Japan
[6] Hitachi Gen Hosp, Dept Hematol, Ibaraki, Japan
[7] Tokyo Med & Dent Univ Hosp, Dept Hematol, Tokyo, Japan
[8] Japanese Red Cross Musashino Hosp, Dept Hematol, Tokyo, Japan
[9] Ome Municipal Gen Hosp, Dept Hematol, Tokyo, Japan
[10] Yokohama City Minato Red Cross Hosp, Dept Hematol, Yokohama, Kanagawa, Japan
[11] Yokosuka Kyosai Hosp, Dept Hematol, Yokosuka, Kanagawa, Japan
[12] Saitama Med Univ Hosp, Dept Hematol, Saitama, Japan
[13] Ibaraki Cent Hosp, Dept Med Oncol, Ibaraki, Japan
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-113788
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2160
引用
收藏
页数：3
相关论文
共 50 条
  • [31] The efficacy and safety of bortezomib plus busulfan/melphalan as conditioning regimen in multiple myeloma undergoing autologous stem cell transplantation: PHASE 1/2 study
    Lee, Jong Hyuk
    Park, Sung-Soo
    Kim, Kihyun
    Lee, Jae Hoon
    Yoon, Sung Soo
    Mun, Yeung Chul
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    BONE MARROW TRANSPLANTATION, 2019, 54 : 501 - 502
  • [32] Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM)
    Nooka, Ajay K.
    Langston, Amelia A.
    Waller, Edmund K.
    Heffner, Leonard T.
    Gleason, Charise
    Muppidi, Samatha
    Watson, Melanie
    Casbourne, Daniela
    Boise, Lawrence
    Kaufman, Jonathan L.
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
    Cavo, Michele
    Tacchetti, Paola
    Patriarca, Francesca
    Petrucci, Maria Teresa
    Pantani, Lucia
    Galli, Monica
    Di Raimondo, Francesco
    Crippa, Claudia
    Zamagni, Elena
    Palumbo, Antonio
    Offidani, Massimo
    Corradini, Paolo
    Narni, Franco
    Spadano, Antonio
    Pescosta, Norbert
    Deliliers, Giorgio Lambertenghi
    Ledda, Antonio
    Cellini, Claudia
    Caravita, Tommaso
    Tosi, Patrizia
    Baccarani, Michele
    LANCET, 2010, 376 (9758): : 2075 - 2085
  • [34] Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.
    Richardson, Paul G.
    Jacobus, Susanna J.
    Weller, Edie
    Hassoun, Hani
    Lonial, Sagar
    Raje, Noopur S.
    Medvedova, Eva
    McCarthy, Philip L.
    Libby, Edward N.
    Voorhees, Peter M.
    Orlowski, Robert Z.
    Anderson, Larry D., Jr.
    Hurd, David D.
    Pasquini, Marcelo C.
    Masone, Kelly
    Moreau, Philippe
    Avet-Loiseau, Herve
    Attal, Michel
    Anderson, Kenneth Carl
    Munshi, Nikhil C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [35] Canadian Retrospective Multicentric Study Comparing the Combination of Bortezomib, Cyclophosphamide and Dexamethasone (Cybord) Versus Bortezomib, Thalidomide and Dexamethasone (VTD) Versus Bortezomib and Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma Eligible for Autologous Hematopoietic Stem Cell Transplantation (HCT)
    Yamga, Eric
    Leblanc, Richard
    Boudreault, Jean-Samuel
    BLOOD, 2018, 132
  • [36] Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial
    Reece, Donna E.
    Rodriguez, Giovanni Piza
    Szwajcer, David
    Minuk, Leonard A.
    Pantoja, Mariela
    Belch, Andrew
    Shustik, Chaim
    Stakiw, Julie
    White, Darrell J.
    Chen, Christine
    Kukreti, Vishal
    Tiedemann, Rodger E.
    Sebag, Michael
    Jenkins, Gayle
    Bahlis, Nizar J.
    Le, Lisa W.
    Trudel, Suzanne
    BLOOD, 2011, 118 (21) : 1704 - 1704
  • [37] Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial
    Kim, Hye Jin
    Yoon, Sung-Soo
    Lee, Dong Soon
    Sohn, Sang Kyun
    Eom, Hyeon Seok
    Lee, Jung Lim
    Chung, Joo Seup
    Kim, Kihyun
    Suh, Cheolwon
    Won, Jong Ho
    Kim, Jin Seok
    Park, Joon Seong
    Kang, Hye Jin
    Seong, Chu Myong
    Kim, Cheol Soo
    Lee, Sang Jae
    Lee, Jae Hoon
    ANNALS OF HEMATOLOGY, 2012, 91 (02) : 249 - 256
  • [38] Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial
    Hye Jin Kim
    Sung-Soo Yoon
    Dong Soon Lee
    Sang Kyun Sohn
    Hyeon Seok Eom
    Jung Lim Lee
    Joo Seup Chung
    Kihyun Kim
    Cheolwon Suh
    Jong Ho Won
    Jin Seok Kim
    Joon Seong Park
    Hye Jin Kang
    Chu Myong Seong
    Cheol Soo Kim
    Sang Jae Lee
    Jae Hoon Lee
    Annals of Hematology, 2012, 91 : 249 - 256
  • [39] Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial
    Rosinol, Laura
    Oriol, Albert
    Rios, Rafael
    Sureda, Anna
    Blanchard, M. Jesus
    Hernandez, Miguel T.
    Martinez-Martinez, Rafael
    Moraleda, Jose M.
    Jarque, Isidro
    Bargay, Juan
    Gironella, Mercedes
    Moreno, Maria Jose
    Palomera, Luis
    Gonzalez-Montes, Yolanda
    Marti, Josep M.
    Krsnik, Isabel
    Arguinano, Jose M.
    Gonzalez, Maria Esther
    Gonzalez, Ana Pilar
    Casado, Felipe
    Lopez-Anglada, Lucia
    Paiva, Bruno
    Mateos, Maria-Victoria
    San Miguel, Jesus F.
    Lahuerta, Juan-Jose
    Blade, Joan
    BLOOD, 2017, 130
  • [40] A Prospective, Multicenter Phase II Study of Consolidation with Cyclophosphamide, Bortezomib and Dexamethasone (CVD) in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation; The KMM130 Study
    Eom, Hyeon-Seok
    Jung, Jongheon
    Kim, Kihyun
    Min, Chang Ki
    Lee, Je-Jung
    Yoon, Sung-Soo
    Lee, Jae Hoon
    Kim, Jin Seok
    Shin, Ho-Jin
    Bang, Soo-Mee
    Sohn, Sang Kyun
    Suh, Cheolwon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E291 - E291
12345